Hikma Pharmaceuticals Plc (LON:HIK) insider Ali Al-Husry purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was bought at an average price of GBX 2,138 ($27.91) per share, with a total value of £1,069,000 ($1,395,379.19).
Ali Al-Husry also recently made the following trade(s):
- On Friday, September 23rd, Ali Al-Husry purchased 50,000 shares of Hikma Pharmaceuticals Plc stock. The stock was bought at an average price of GBX 2,099 ($27.40) per share, with a total value of £1,049,500 ($1,369,925.60).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2076.00 on Tuesday. The firm’s market capitalization is GBX 4.69 billion. The company’s 50 day moving average price is GBX 2,192.94 and its 200 day moving average price is GBX 2,241.67. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00.
A number of research firms have weighed in on HIK. Jefferies Group decreased their price target on Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a “buy” rating for the company in a report on Monday, September 12th. Barclays PLC restated an “overweight” rating and issued a GBX 2,800 ($36.55) price target on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 4th. Numis Securities Ltd restated a “hold” rating and issued a GBX 2,660 ($34.72) price target on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, August 24th. Stifel Nicolaus restated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, June 24th. Finally, Morgan Stanley decreased their price target on Hikma Pharmaceuticals Plc from GBX 2,700 ($35.24) to GBX 2,500 ($32.63) and set an “equal weight” rating for the company in a report on Friday, August 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Hikma Pharmaceuticals Plc presently has an average rating of “Buy” and an average price target of GBX 2,520.90 ($32.91).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.